The combination of accelerating revenue growth, improving profitability, and multiple near-term catalysts (KarXT launch, VYVGART regulatory decisions, zoci data readouts) positions Zai Lab for sustained outperformance. The company's transition toward profitability while advancing its pipeline suggests strong execution capability.
ZLAB drugs
ZLAB drug pipeline →Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Zai Lab reported strong financial results for Q4 and full-year 2025, with total revenue growing 17% YoY to $127.6 million in Q4 and 15% YoY to $460.2 million for the full year. The company achieved a 41% reduction in net loss to $175.5 million, driven by revenue growth outpacing expenses and improved foreign exchange performance. Key developments include the approval and upcoming commercial launch of KarXT in China, advancement of its global oncology pipeline including zoci, and positive clinical data for VYVGART in ocular myasthenia gravis.
Key Financial Metrics
Key Facts
- Total revenue grew 17% YoY to $127.6 million in Q4 2025 and 15% YoY to $460.2 million for full-year 2025
- Net loss decreased 32% YoY to $175.5 million for full-year 2025, with Q4 net loss down 38% to $50.4 million
- KarXT approved in China for schizophrenia treatment and commercial launch planned for H1 2026
- VYVGART Phase 3 trial met primary endpoint for ocular myasthenia gravis with statistically significant improvement
- FDA accepted Priority Review for VYVGART sBLA for seronegative gMG with PDUFA date of May 10, 2026
Financial Impact
Revenue growth of $61.2 million YoY with $81.6 million reduction in net loss
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| ZEJULA | $189.0M | +1.0% |
| VYVGART and VYVGART Hytrulo | $94.2M | +1.0% |
| XACDURO | $22.9M | +593.0% |
| NUZYRA | $60.8M | +41.0% |
Risk Factors
- Continued operating losses despite improvement
- Dependence on successful commercialization of new products like KarXT
- Pipeline development risks for zoci and other candidates
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001704292-26-000014 |
| Document: zlab-20260226.htm | 0001704292-26-000014 |
| Document: 0001704292-26-000014-index-headers.html | 0001704292-26-000014 |
| Document: 0001704292-26-000014-index.html | 0001704292-26-000014 |
| Document: 0001704292-26-000014.txt | 0001704292-26-000014 |
Track record
23 reports on ZLAB
3 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +13.13% at T+20 after the May 7, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
- Nov 5, 202611d ago 8-K Neutral 5/10 Entry $22.60 to $25.48 Now $23.47 +3.85% ▲ +12.74% +12.43% vs SPY
- Oct 23, 202624d ago 8-K Bullish 6/10 Entry $24.03 to $24.34 Now $23.47 −2.33% ▲ +1.29% +0.58% vs SPY
- Aug 21, 202612w ago Insider Cluster Neutral 2/10 Entry $25.64 to $26.17 Now $23.47 −8.46% ▲ +2.07% +1.75% vs SPY
- Aug 13, 202613w ago Insider Cluster Neutral 2/10 Entry $25.90 to $25.64 Now $23.47 −9.38% ▼ −1.00% −0.53% vs SPY
- Aug 13, 202613w ago Insider Cluster Neutral 2/10 Entry $25.90 to $25.64 Now $23.47 −9.38% ▼ −1.00% −0.53% vs SPY
- Aug 12, 202613w ago 144 Neutral 2/10 Entry $25.49 to $26.03 Now $23.47 −7.92% ▲ +2.12% +1.42% vs SPY
- Jul 1, 202619w ago Insider Cluster Neutral 2/10 Entry $19.12 to $19.08 Now $23.47 +22.75% ▼ −0.21% −1.08% vs SPY
- Jun 29, 202620w ago Insider Cluster Neutral 3/10 Entry $19.00 to $19.15 Now $23.47 +23.53% ▲ +0.79% +0.92% vs SPY
- Jun 11, 202622w ago Institutional Cluster Bearish 5/10 Entry $17.64 to $17.07 Now $23.47 −33.05% ▲ +3.23% +3.77% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers